Hong Kong stock concept tracking | Deepseek triggers AI medical boom, boosting pharmaceutical sector valuation (attached concept stocks)

In 2024, the total number of outpatient visits in medical and health institutions nationwide was 10.11 billion, an increase of 5.8% year-on-year. In 2024, the total income of the national basic medical insurance fund was 3.48 trillion yuan, an increase of 4.4% year-on-year, with total expenditure of 2.97 trillion yuan, an increase of 5.5% year-on-year, indicating a slight slowdown in the rapid growth of expenditure. Frost & Sullivan predicts that by 2033, the market size of the AI medical industry in China will increase from 8.8 billion yuan in 2023 to 315.7 billion yuan, with a compound annual growth rate of 43.1%. DeepSeek has triggered a wave of AI medical applications, boosting the valuation of the pharmaceutical sector. Since the beginning of 2025, DeepSeek has sparked a wave of AI medical applications, with companies in the industry quickly deploying localized applications of DeepSeek, significantly improving the performance of professional large models. AI will widen the gap between industry leaders and followers, helping to increase market share in core businesses, and derive new services and functionalities from AI applications, bringing incremental growth to the industry in the long term. China Galaxy Securities released a research report stating that in terms of AI medical applications, new drug research and development, intelligent equipment, diagnostic services, and physical examination services are expected to advance rapidly, potentially enhancing the valuation of the pharmaceutical sector. Tianfeng Research report stated that with the opening of the AI era, the core contradiction in AI medical technology is shifting from a "big model + computing power arms race" to a "revaluation of data value." The medical industry, as a highly specialized industry with high barriers, will have the opportunity to achieve leapfrog growth by having high-quality data, rare application scenarios, and mastering the race track and enterprises with multimodal fusion data. It is recommended to focus on directions related to high-quality data, rare application scenarios, and multimodal fusion data, such as AI + health management, AI + detection diagnosis and treatment, AI + doctor digital platform, AI + medical informationization, and AI + drug development. AI medical-related Hong Kong stocks include: Crystal Optech (2228), ALI HEALTH (0241), JD HEALTH (6618), Ping An Health (1833), YIDU TECH (2158), Microc Siasun Robot&Automation (2252), Gu Sheng Tang (2273), MEDLIVE (2192), etc. iFLYTEK Medical (02506): As the only medical deep reasoning large model trained with national-produced computing power, the X1 Starfire Medical Large Model's performance in medical tasks such as diagnostic recommendations and health consultations surpasses that of GPT-4o and DeepSeek R1, marking a major technological breakthrough in the field of AI medical technology. Iflytek Co.,ltd. has launched the iFLYTEK Starfire Medical All-in-One Machine in partnership with Huawei, which is based on the technical ability of the X1 Starfire Medical Large Model, supporting full-stack localization, rapid deployment, out-of-the-box use, data non-exit domain, and data security. HEC CJ PHARM (01558): Since 2023, Guangdong Hec Technology Holding has cooperated with Huawei Cloud in AI drug research and development, optimizing the high-precision molecular properties and drug structures. From drug discovery to pharmaceutical processes, a one-stop out-of-the-box large model drug research platform has been created. On December 16th last year, Guangdong Hec Technology Holding's AI-driven Class 1 new drug, the first small molecule innovative drug HEC169584, was approved for clinical trials for non-alcoholic fatty liver disease (NASH). HEC169584 is the first candidate drug obtained by Guangdong Hec Technology Holding through AI-driven small molecule drug design platform. YIDU TECH (02158): YIDU TECH is committed to promoting cutting-edge innovation in AI medical technology, using the "AI Medical Brain" YiduCore to create professional, efficient, precise, and inclusive artificial intelligence products and solutions in public health, clinical and disease research, medical management, new drug research and health management fields. Recently, YIDU TECH announced the integration of the DeepSeek artificial intelligence model into its self-developed "AI Medical Brain" YiduCore, which will further promote the large-scale application and innovative practice of AI technology in the medical and health industry. Ping An Health (01833): Building on its "Ping An Medical Note" multimodal large model and "Ping An Family Doctor" doctor workstation, Ping An Health has recently completed the deployment of DeepSeek and some scenario applications. Access to DeepSeek signifies a transition from pure digital services to comprehensive intelligence. By integrating DeepSeek's strong computing power and algorithm advantages, the deep application of AI technology in medical services, Ping An Health's user base and revenue levels are expected to further improve, driving the growth of the company's valuation. JD HEALTH (06618): In January of this year, the company released the industry's first hospital full-scenario application large model product "JD Zhuoyi", announcing the official launch of the first batch of digital doctors on the Internet doctor platform. In February, it was announced that the company's self-owned medical large model "Jingyi Qianxun" has been integrated with general models such as GPT series, DeepSeek, and has been open sourced, meaning that all model parameters, data construction, multi-stage model training, model evaluation and other core code will be public.